Is MOTS-c Legal? Global Status Guide
Category: Metabolic · Tracked in 158 countries
29
Legal1
Research Only125
Grey Area3
BannedCan You Buy MOTS-c?
Whether you can buy MOTS-c depends on your country. It is legal to purchase in 29 countries, including Jamaica, Dominican Republic, Bahamas, Trinidad and Tobago, Barbados, Cayman Islands, Aruba, Curacao, and 21 more. It falls into a legal grey area in 125 countries (United States, Australia, Canada, Germany, France, Netherlands, Sweden, Norway, and 117 more), where it may be available for research but not for human use. It is banned in 3 countries: Cuba, China, Singapore.
Traveling with MOTS-c
Traveling internationally with MOTS-c requires understanding local laws at your destination. Do not carry MOTS-c into countries where it is banned (Cuba, China, Singapore) — you could face serious legal consequences. Always declare pharmaceutical products at customs and check the latest regulations before traveling.
Need to calculate your MOTS-c dosage? Use the MOTS-c reconstitution calculator on peptide.locker
MOTS-c Legal Status by Country (158)
| Country | Status | Rx Required | Schedule | Detail |
|---|---|---|---|---|
| Anguilla | Legal | No | Not Scheduled | Not specifically regulated. |
| Antigua and Barbuda | Legal | No | Not Scheduled | Not specifically regulated. |
| Aruba | Legal | No | Unregistered | Not specifically regulated. |
| Bahamas | Legal | No | Unregistered | Not specifically regulated. |
| Barbados | Legal | No | Unregistered | Not specifically regulated. |
| Bosnia and Herzegovina | Legal | No | Not Registered | Non-EU. Not registered. Research peptide. WADA banned. No regulatory framework covers this compound. |
| British Virgin Islands | Legal | No | Not Scheduled | Not specifically regulated. |
| Cayman Islands | Legal | No | Unregistered | Not specifically regulated. |
| Costa Rica | Legal | No | Unregistered | Not specifically regulated. |
| Curacao | Legal | No | Unregistered | Not specifically regulated. |
| Dominica | Legal | No | Not Scheduled | Not specifically regulated. |
| Dominican Republic | Legal | No | Unregistered | Not specifically regulated. |
| Georgia | Legal | No | Not Registered | Non-EU. Not registered. Research peptide. WADA banned. No regulatory framework covers this compound. |
| Grenada | Legal | No | Not Scheduled | Not specifically regulated. |
| Jamaica | Legal | No | Unregistered | Not specifically regulated. |
| Montenegro | Legal | No | Not Registered | Non-EU. Not registered. Research peptide. WADA banned. No regulatory framework covers this compound. |
| Montserrat | Legal | No | Not Scheduled | Not specifically regulated. |
| North Macedonia | Legal | No | Not Registered | Non-EU. Not registered. Research peptide. WADA banned. No regulatory framework covers this compound. |
| Papua New Guinea | Legal | No | Not Scheduled | Not regulated. Novel peptide unknown to PNG regulators. No enforcement. |
| Samoa | Legal | No | Not Scheduled | Not regulated. Novel peptide unknown to Samoan regulators. |
| Serbia | Legal | No | Not Registered | Non-EU. Not registered. Research peptide. No regulatory framework specifically covers this compound. WADA banned. |
| St Kitts and Nevis | Legal | No | Not Scheduled | Not specifically regulated. |
| St Lucia | Legal | No | Not Scheduled | Not specifically regulated. |
| St Vincent and the Grenadines | Legal | No | Not Scheduled | Not specifically regulated. |
| Tonga | Legal | No | Not Scheduled | Not regulated. Novel peptide unknown to Tongan regulators. |
| Trinidad and Tobago | Legal | No | Unregistered | Not specifically regulated. |
| Turks and Caicos | Legal | No | Not Scheduled | Not specifically regulated. |
| Ukraine | Legal | No | Not Registered | Non-EU. Not registered. Research peptide. WADA banned. No regulatory framework covers this compound. |
| Vanuatu | Legal | No | Not Scheduled | Not regulated. Unknown to Vanuatu regulators. |
| United Kingdom | Research Only | No | Not Scheduled | Not controlled. Available for research purchase. |
| Algeria | Grey Area | No | Unregistered | Novel peptide. Not ANPP registered. Import restrictions apply. |
| Andorra | Grey Area | No | Not Scheduled | Not authorized. Unknown to AMA. |
| Angola | Grey Area | No | Unregistered | Novel peptide. Not addressed by INABEC. No local availability. |
| Argentina | Grey Area | No | Unregistered | Not specifically regulated. Minimal availability. |
| Australia | Grey Area | No | Not Specifically Scheduled | Not specifically scheduled in Poisons Standard. Not a GHRP/GHRH/GHS so not captured by class entries. Likely treated as unapproved therapeutic good. |
| Austria | Grey Area | No | Not Scheduled / Unauthorized | Research peptide. No EMA authorization. WADA banned. Minimal enforcement attention. |
| Bahrain | Grey Area | No | Unregistered | Not specifically regulated. |
| Bangladesh | Grey Area | No | Not Scheduled | Not registered. Novel peptide unknown to DGDA. |
| Belgium | Grey Area | No | Not Scheduled / Unauthorized | Research peptide. No EMA authorization. WADA banned. Minimal enforcement attention. |
| Belize | Grey Area | No | Unregistered | Not specifically regulated. Minimal availability. |
| Bolivia | Grey Area | No | Unregistered | Not specifically regulated. Minimal availability. |
| Bonaire | Grey Area | No | Not Scheduled | Not specifically regulated. |
| Botswana | Grey Area | No | Unregistered | Novel peptide. Not addressed by BoMRA. No local availability. |
| Brazil | Grey Area | No | Unregistered | Not specifically regulated. Minimal availability. |
| Brunei | Grey Area | No | Not Scheduled | Not registered. Would be treated as unauthorized medicinal product. |
| Bulgaria | Grey Area | No | Not Scheduled / Unauthorized | Research peptide. No EMA authorization. WADA banned. Minimal enforcement attention. |
| Cambodia | Grey Area | No | Unregistered | Not specifically regulated. |
| Cameroon | Grey Area | No | Unregistered | Novel peptide. Not addressed by DPML. No local availability. |
| Canada | Grey Area | No | Not Scheduled (CDSA) | Not specifically named in enforcement actions. No DIN. Technically unauthorized if marketed for human use. |
| Cape Verde | Grey Area | No | Unregistered | Novel peptide. Not addressed by ARFA. No local availability. |
| Chile | Grey Area | No | Unregistered | Not specifically regulated. Minimal availability. |
| Colombia | Grey Area | No | Unregistered | Not specifically regulated. Minimal availability. |
| Croatia | Grey Area | No | Not Scheduled / Unauthorized | Research peptide. No EMA authorization. WADA banned. Minimal enforcement attention. |
| Cyprus | Grey Area | No | Not Scheduled | No marketing authorization. Would be treated as unauthorized medicinal product under EU law. |
| Czech Republic | Grey Area | No | Not Scheduled / Unauthorized | Research peptide. No EMA authorization. WADA banned. Minimal enforcement attention. |
| Democratic Republic of Congo | Grey Area | No | Unregistered | Novel peptide. Not addressed by ACOREP. No local availability. |
| Denmark | Grey Area | No | Not Scheduled / Unauthorized | Research peptide. No EMA authorization. WADA banned. Minimal enforcement attention. |
| Ecuador | Grey Area | No | Unregistered | Not specifically regulated. Minimal availability. |
| Egypt | Grey Area | No | Unregistered | Not specifically regulated. |
| El Salvador | Grey Area | No | Unregistered | Not specifically regulated. Minimal availability. |
| Estonia | Grey Area | No | Not Scheduled / Unauthorized | Research peptide. No EMA authorization. WADA banned. Minimal enforcement attention. |
| Ethiopia | Grey Area | No | Unregistered | Novel peptide. Not specifically addressed by EFDA. No local availability. Minimal regulatory attention. |
| Fiji | Grey Area | No | Unregistered | Not specifically regulated. Not locally available. |
| Finland | Grey Area | No | Not Scheduled / Unauthorized | Research peptide. No EMA authorization. WADA banned. Minimal enforcement attention. |
| France | Grey Area | No | Not Scheduled / Unauthorized | Research peptide. No EMA authorization. WADA banned. Minimal enforcement attention. |
| French Guiana | Grey Area | No | Unauthorized Medicine | Not approved under French framework. |
| Germany | Grey Area | No | Not Scheduled / Unauthorized | Research peptide. No EMA authorization. WADA banned. Minimal enforcement attention. |
| Ghana | Grey Area | No | Unregistered | Not specifically regulated. |
| Greece | Grey Area | No | Not Scheduled / Unauthorized | Research peptide. No EMA authorization. WADA banned. Minimal enforcement attention. |
| Guatemala | Grey Area | No | Unregistered | Not specifically regulated. Minimal availability. |
| Guyana | Grey Area | No | Unregistered | Not specifically regulated. Minimal availability. |
| Honduras | Grey Area | No | Unregistered | Not specifically regulated. Minimal availability. |
| Hong Kong | Grey Area | No | Unregistered | Not specifically regulated. |
| Hungary | Grey Area | No | Not Scheduled / Unauthorized | Research peptide. No EMA authorization. WADA banned. Minimal enforcement attention. |
| Iceland | Grey Area | No | Unauthorized Medicine | Not EMA authorized. Postal import prohibited for medicines from non-EEA countries. |
| India | Grey Area | No | Unregistered | Not specifically regulated. |
| Indonesia | Grey Area | No | Unregistered | Not specifically regulated. |
| Iran | Grey Area | No | Not Scheduled | Not registered. Novel peptide. Sanctions prevent import. |
| Iraq | Grey Area | No | Not Scheduled | Not registered. Could enter through unregulated channels. |
| Ireland | Grey Area | No | Not Scheduled / Unauthorized | Research peptide. No EMA authorization. WADA banned. Minimal enforcement attention. |
| Israel | Grey Area | No | Unregistered | Not specifically regulated. |
| Italy | Grey Area | No | Not Scheduled / Unauthorized | Research peptide. No EMA authorization. WADA banned. Minimal enforcement attention. |
| Ivory Coast | Grey Area | No | Unregistered | Novel peptide. Not addressed by AIRP. No local availability. |
| Japan | Grey Area | No | Unregistered | Not specifically regulated. |
| Jordan | Grey Area | No | Unregistered | Not specifically regulated. |
| Kenya | Grey Area | No | Unregistered | Not specifically regulated. Not available locally. Novel peptide. |
| Kuwait | Grey Area | No | Unregistered | Not specifically regulated. |
| Laos | Grey Area | No | Unregistered | Not specifically regulated. Not locally available. |
| Latvia | Grey Area | No | Not Scheduled / Unauthorized | Research peptide. No EMA authorization. WADA banned. Minimal enforcement attention. |
| Lebanon | Grey Area | No | Not Scheduled | Not registered. Unknown to Lebanese regulators. |
| Libya | Grey Area | No | Unregistered | Novel peptide. Not addressed by NCDCR. No local availability. |
| Liechtenstein | Grey Area | No | Not Scheduled | No marketing authorization. Unauthorized under EEA pharmaceutical framework. |
| Lithuania | Grey Area | No | Not Scheduled / Unauthorized | Research peptide. No EMA authorization. WADA banned. Minimal enforcement attention. |
| Luxembourg | Grey Area | No | Not Scheduled | No marketing authorization. Unauthorized under EU pharmaceutical law. |
| Madagascar | Grey Area | No | Unregistered | Novel peptide. Not addressed by AMM. No local availability. |
| Malawi | Grey Area | No | Unregistered | Novel peptide. Not addressed by PMRA. No local availability. |
| Malaysia | Grey Area | No | Unregistered | Not specifically regulated. |
| Maldives | Grey Area | No | Unregistered | Not specifically regulated. Not locally available. |
| Malta | Grey Area | No | Unauthorized Medicine | Not EMA authorized. Would require marketing authorization for any therapeutic claims. |
| Mauritius | Grey Area | No | Unregistered | Not specifically regulated. |
| Mexico | Grey Area | No | Unregistered | Research chemical. Very limited domestic availability. |
| Monaco | Grey Area | No | Not Scheduled | No marketing authorization. Unauthorized under French/EU pharmaceutical framework. |
| Morocco | Grey Area | No | Unregistered | Not specifically regulated. Not available through any Moroccan channel. Would need to import. |
| Mozambique | Grey Area | No | Unregistered | Novel peptide. Not addressed by ANARME. No local availability. |
| Myanmar | Grey Area | No | Unregistered | Not specifically regulated. Not locally available. |
| Namibia | Grey Area | No | Unregistered | Not specifically regulated. |
| Nepal | Grey Area | No | Unregistered | Not specifically regulated. Not locally available. |
| Netherlands | Grey Area | No | Not Scheduled / Unauthorized | Research peptide. No EMA authorization. WADA banned. Minimal enforcement attention. |
| New Zealand | Grey Area | No | Unregistered | Not specifically regulated. |
| Nicaragua | Grey Area | No | Unregistered | Not specifically regulated. Minimal availability. |
| Nigeria | Grey Area | No | Unregistered | Not specifically regulated. Not available locally. |
| Norway | Grey Area | No | Not Scheduled / Unauthorized | Research peptide. No EMA authorization. WADA banned. Minimal enforcement attention. |
| Oman | Grey Area | No | Unregistered | Not specifically regulated. |
| Pakistan | Grey Area | No | Not Scheduled | Not registered. Novel peptide unknown to DRAP. |
| Panama | Grey Area | No | Unregistered | Not specifically regulated. Minimal availability. |
| Paraguay | Grey Area | No | Unregistered | Not specifically regulated. Minimal availability. |
| Peru | Grey Area | No | Unregistered | Not specifically regulated. Minimal availability. |
| Philippines | Grey Area | No | Unregistered | Not specifically regulated. |
| Poland | Grey Area | No | Not Scheduled / Unauthorized | Research peptide. No EMA authorization. WADA banned. Minimal enforcement attention. |
| Portugal | Grey Area | No | Not Scheduled / Unauthorized | Research peptide. No EMA authorization. WADA banned. Minimal enforcement attention. |
| Qatar | Grey Area | No | Unregistered | Not specifically regulated. |
| Romania | Grey Area | No | Not Scheduled / Unauthorized | Research peptide. No EMA authorization. WADA banned. Minimal enforcement attention. Mitochondrial-derived peptide. |
| Russia | Grey Area | No | Unregistered | Not specifically regulated. |
| Rwanda | Grey Area | No | Unregistered | Not specifically regulated. |
| Saba | Grey Area | No | Not Scheduled | Not specifically regulated. |
| Saint Barthelemy | Grey Area | No | Unauthorized Medicine | Not approved under French framework. |
| Saint Martin (French) | Grey Area | No | Unauthorized Medicine | Not approved under French framework. |
| Saudi Arabia | Grey Area | No | Unregistered | Not specifically regulated. |
| Senegal | Grey Area | No | Unregistered | Not specifically regulated. |
| Seychelles | Grey Area | No | Unregistered | Not specifically regulated. Not locally available. |
| Sint Eustatius | Grey Area | No | Not Scheduled | Not specifically regulated. |
| Sint Maarten | Grey Area | No | Not Scheduled | Not specifically regulated. |
| Slovakia | Grey Area | No | Not Scheduled / Unauthorized | Research peptide. No EMA authorization. WADA banned. Minimal enforcement attention. |
| Slovenia | Grey Area | No | Not Scheduled / Unauthorized | Research peptide. No EMA authorization. WADA banned. Minimal enforcement attention. |
| South Africa | Grey Area | No | Unregulated | Not specifically regulated. Novel mitochondrial peptide. Available from research vendors. Minimal SAHPRA attention. Same research chemical framework as BPC-157. |
| South Korea | Grey Area | No | Unregistered | Not specifically regulated. |
| Spain | Grey Area | No | Not Scheduled / Unauthorized | Research peptide. No EMA authorization. WADA banned. Minimal enforcement attention. |
| Sri Lanka | Grey Area | No | Unregistered | Not registered. Not specifically regulated. |
| Suriname | Grey Area | No | Unregistered | Not specifically regulated. Minimal availability. |
| Sweden | Grey Area | No | Not Scheduled / Unauthorized | Research peptide. No EMA authorization. WADA banned. Minimal enforcement attention. |
| Switzerland | Grey Area | No | Not Scheduled / Unauthorized | Research peptide. No EMA authorization. WADA banned. Minimal enforcement attention. |
| Taiwan | Grey Area | No | Unregistered | Not specifically regulated. |
| Tanzania | Grey Area | No | Unregistered | Not specifically regulated. |
| Thailand | Grey Area | No | Unregistered | Not specifically regulated. |
| Tunisia | Grey Area | No | Unregistered | Not specifically regulated. Not available locally. |
| Turkey | Grey Area | No | Unregistered | Not specifically regulated. |
| Uganda | Grey Area | No | Unregistered | Novel peptide. Not addressed by NDA. No local availability. |
| United Arab Emirates | Grey Area | No | Unregistered | Not specifically regulated. |
| United States | Grey Area | No | Not Scheduled | Mitochondrial-derived peptide. Not specifically regulated or targeted by FDA. Available as research chemical. Minimal enforcement attention. |
| Uruguay | Grey Area | No | Unregistered | Not specifically regulated. Minimal availability. |
| US Virgin Islands | Grey Area | No | Not Scheduled | Same as US. Research chemical. Minimal enforcement. |
| Venezuela | Grey Area | No | Unregistered | Not specifically regulated. Minimal availability. |
| Vietnam | Grey Area | No | Unregistered | Not specifically regulated. |
| Zambia | Grey Area | No | Unregistered | Novel peptide. Not addressed by ZAMRA. No local availability. |
| Zimbabwe | Grey Area | No | Unregistered | Novel peptide. Not addressed by MCAZ. No local availability. |
| China | Banned | No | Unapproved Drug | Not approved for consumer use. |
| Cuba | Banned | No | State Controlled | State pharmaceutical monopoly via CECMED/BioCubaFarma. No private purchase/import permitted. |
| Singapore | Banned | No | Unapproved Health Product | Unapproved. Do not import. |
Data is researcher-verified but not legal advice. Regulations change frequently. Always verify with local authorities before purchasing, importing, or traveling with peptides. Last verified: 2026-02-28.